首頁 > 市場調查報告書 > 醫療設備

婦科治療

全球子宮肌瘤治療藥物市場研究報告 - 2023 年至 2030 年產業分析、規模、佔有率、成長、趨勢與預測

市場調查報告書

商品編碼

1377903

全球子宮肌瘤治療藥物市場研究報告 - 2023 年至 2030 年產業分析、規模、佔有率、成長、趨勢與預測

Global Uterine Fibroid Treatment Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年09月01日 | 出版商:

Value Market Research | 英文 172 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球子宮肌瘤治療藥物市場需求預計將從 2022 年的 22.9 億美元增至 2030 年的近 56.3 億美元，2023-2030 年研究期間CAGR為 11.9%。

子宮肌瘤治療藥物是用來控制子宮肌瘤症狀的藥物，子宮肌瘤是子宮壁上生長的生長物或腫瘤（非癌性）。這些藥物通常在不需要立即進行手術或首選侵入性較小的方法時使用。這些藥物可能會導致月經大量出血、骨盆腔疼痛和壓力，這些藥物的目的是緩解這些症狀。

市場動態：

子宮肌瘤治療藥物市場由反映子宮肌瘤的盛行率及其對女性健康影響的多個因素所推動。子宮肌瘤是一種常見的婦科疾病，導致對治療相關症狀的藥物的持續需求。月經大量出血、骨盆腔疼痛和壓力是促使患者尋求藥物介入以提高生活品質的常見症狀。許多女性喜歡非手術治療方案，以避免與手術相關的潛在風險和恢復。子宮肌瘤治療藥物提供了一種侵入性較小的替代方案。此外，一些患有肌瘤的女性希望保留生育能力，因此保留子宮的藥物成為一個有吸引力的選擇。藥物開發的不斷進步和患者意識的提高有助於擴大可用治療選擇的範圍。臨床指引和盡量減少失血（肌瘤的常見症狀）的願望進一步支持這些藥物的使用。子宮肌瘤治療藥物也在個人化醫療中發揮作用，可以根據患者的個別需求制定量身定做的治療計劃。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球子宮肌瘤治療藥物市場的各個細分市場進行了包容性評估。子宮肌瘤治療藥物產業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲子宮肌瘤治療藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。子宮肌瘤治療藥物市場的主要參與者包括Myovant Sciences GmbH、輝瑞公司、艾伯維公司、Ferring BV、阿斯特捷利康、拜耳公司、Amring Pharmaceuticals Inc.、沃森製藥公司。本節包括競爭格局的整體視圖其中包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：子宮肌瘤治療藥物公司的競爭格局

子宮肌瘤治療藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
Myovant Sciences GmbH

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Abbvie Inc.

公司簡介
公司收入
產品
最近的發展

Ferring BV

公司簡介
公司收入
產品
最近的發展

AstraZeneca

公司簡介
公司收入
產品
最近的發展

Bayer AG

公司簡介
公司收入
產品
最近的發展

Amring Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

Watson Pharma Inc.

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112112210

The global demand for Uterine Fibroid Treatment Drugs Market is presumed to reach the market size of nearly USD 5.63 BN by 2030 from USD 2.29 BN in 2022 with a CAGR of 11.9% under the study period 2023 - 2030.

Uterine fibroid treatment drugs are medications prescribed to manage the symptoms of uterine fibroids, which are growths or tumors (non-cancerous) that develop in the wall of the uterus. These drugs are typically used when surgery is not immediately necessary or when a less invasive approach is preferred. These can cause heavy menstrual bleeding, pelvic pain, and pressure, and the goal of these medications is to alleviate these symptoms.

MARKET DYNAMICS:

The Uterine fibroid treatment drugs market is driven by several factors reflecting the prevalence and impact of uterine fibroids on women's health. Uterine fibroids are a common gynecological condition, leading to a consistent demand for medications to manage associated symptoms. Heavy menstrual bleeding, pelvic pain, and pressure are common symptoms that drive patients to seek pharmaceutical interventions enhancing their quality of life. Non-surgical treatment options are preferred by many women to avoid the potential risks and recovery associated with surgery. Uterine fibroid treatment drugs offer a less invasive alternative. Additionally, some women with fibroids aim to preserve fertility, making uterine-sparing medications an appealing choice. Ongoing advancements in drug development and increasing patient awareness contribute to the expanding range of available treatment options. Clinical guidelines and the desire to minimize blood loss, a common symptom of fibroids, further support the use of these medications. Uterine fibroid treatment drugs also play a role in personalized medicine, allowing tailored treatment plans to address individual patient needs.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of uterine fibroid treatment drugs. The growth and trends of uterine fibroid treatment drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the uterine fibroid treatment drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Gonadotropin-Releasing Hormone (GnRH) Agonists
Gonadotropin-Releasing Hormone (GnRH) Antagonists
Progestin-Releasing Intrauterine Device (IUD) & Contraceptives
Non-Hormonal Medications
Others

By Type

Subserosal Fibroids
Intramural Fibroids
Submucosal Fibroids
Pedunculated Fibroids

By End-User

Hospital Pharmacies
Retail Pharmacies
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Uterine Fibroid Treatment Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Uterine Fibroid Treatment Drugs market include Myovant Sciences GmbH, Pfizer Inc., Abbvie Inc, Ferring B.V., AstraZeneca, Bayer AG, Amring Pharmaceuticals Inc., Watson Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . UTERINE FIBROID TREATMENT DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By End-User
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Gonadotropin-Releasing Hormone (GnRH) Agonists Historic and Forecast Sales by Regions
5.5 Gonadotropin-Releasing Hormone (GnRH) Antagonists Historic and Forecast Sales by Regions
5.6 Progestin-Releasing Intrauterine Device (IUD) & Contraceptives Historic and Forecast Sales by Regions
5.7 Non-Hormonal Medications Historic and Forecast Sales by Regions
5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Subserosal Fibroids Historic and Forecast Sales by Regions
6.5 Intramural Fibroids Historic and Forecast Sales by Regions
6.6 Submucosal Fibroids Historic and Forecast Sales by Regions
6.7 Pedunculated Fibroids Historic and Forecast Sales by Regions

7 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY END-USER

7.1 Overview by End-User
7.2 Historical and Forecast Data
7.3 Analysis by End-User
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE UTERINE FIBROID TREATMENT DRUGS COMPANIES

9.1. Uterine Fibroid Treatment Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF UTERINE FIBROID TREATMENT DRUGS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Myovant Sciences GmbH
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Pfizer Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Abbvie Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Ferring B.V.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. AstraZeneca
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Bayer AG
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Amring Pharmaceuticals Inc.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Watson Pharma Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

簡介目錄圖表

LIST OF TABLES

Market Snapshot
Drivers : Impact Analysis
Restraints : Impact Analysis
List of Raw Material
List of Raw Material Manufactures
List of Potential Buyers
Analysis by Drug Class (USD MN)
Gonadotropin-Releasing Hormone (GnRH) Agonists Market Sales by Geography (USD MN)
Gonadotropin-Releasing Hormone (GnRH) Antagonists Market Sales by Geography (USD MN)
Progestin-Releasing Intrauterine Device (IUD) & Contraceptives Market Sales by Geography (USD MN)
Non-Hormonal Medications Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Analysis Market by Type (USD MN)
Subserosal Fibroids Market Sales by Geography (USD MN)
Intramural Fibroids Market Sales by Geography (USD MN)
Submucosal Fibroids Market Sales by Geography (USD MN)
Pedunculated Fibroids Market Sales by Geography (USD MN)
Analysis by End-User (USD MN)
Hospital Pharmacies Market Sales by Geography (USD MN)
Retail Pharmacies Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global Uterine Fibroid Treatment Drugs Market Sales by Geography (USD MN)
North America Market Analysis (USD MN)
United State Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate by Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Uterine Fibroid Treatment Drugs Report
Market Research Process
Market Research Methodology
Global Uterine Fibroid Treatment Drugs Market Size, by Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis by Drug Class
Market Attractiveness Analysis by Type
Market Attractiveness Analysis by End-User
Market Attractiveness Analysis by Region
Value Chain Analysis
Global Market Analysis by Drug Class (USD MN)
Gonadotropin-Releasing Hormone (GnRH) Agonists Market Sales by Geography (USD MN)
Gonadotropin-Releasing Hormone (GnRH) Antagonists Market Sales by Geography (USD MN)
Progestin-Releasing Intrauterine Device (IUD) & Contraceptives Market Sales by Geography (USD MN)
Non-Hormonal Medications Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global Market Analysis by Type (USD MN)
Subserosal Fibroids Market Sales by Geography (USD MN)
Intramural Fibroids Market Sales by Geography (USD MN)
Submucosal Fibroids Market Sales by Geography (USD MN)
Pedunculated Fibroids Market Sales by Geography (USD MN)
Global Market Analysis by End-User (USD MN)
Hospital Pharmacies Market Sales by Geography (USD MN)
Retail Pharmacies Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis